Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 6/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.31 |
| ▸ | PLG | P00747 | 3/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.31 |
| ▸ | PSMB10 | P40306 | 3/20 | 0.31 |
| ▸ | ITGAV | P06756 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19695848 | 0.96 | MME (0.32) | MMEANPEPPSMB2PSMB10 | |
| SCHEMBL17459567 | 0.96 | MME (0.32) | MMEANPEPPSMB2PSMB10 | |
| SCHEMBL17532330 | 0.94 | MME (0.32) | MMEANPEPPSMB2PSMB10 | |
| SCHEMBL17532356 | 0.94 | MME (0.32) | MMEANPEPPSMB2PSMB10 | |
| SCHEMBL17532314 | 0.94 | ITGB3 (0.34) | ITGB3ITGA2BMMEANPEPPLG | |
| SCHEMBL17532361 | 0.92 | MME (0.33) | MMEANPEPPSMB2PSMB10 | |
| SCHEMBL22167229 | 0.91 | PLG (0.33) | ITGB3ITGA2BPLGPRSS1PRSS2 | |
| SCHEMBL17532334 | 0.90 | DGAT1 (0.33) | PSMB2PSMB10 | |
| SCHEMBL17532318 | 0.90 | MME (0.33) | MMEANPEPPSMB2PSMB10 | |
| SCHEMBL22167479 | 0.90 | KIFC1 (0.35) | ITGB3ITGA2BMMEPSMB2ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3172199-B1 | PYRIMIDINE DERIVATIVES AS GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-07-01 | — | — | EP | disclosed |
| US-9839664-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-12-12 | — | — | US | disclosed |
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-08-03 | — | — | US | disclosed |
| US-9474755-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SARL (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | ITGB3 3314/4885ITGA2B 3336/4885MME 1336/4885 |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | ITGB3 3314/4885ITGA2B 3336/4885MME 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.